Evidence map›Paper›PMID 42850382›Full record

ArticleBritish journal of cancer2026

LAIR1 suppresses phagocytosis via SHP2/USP22-mediated MYH9 degradation in glioma-associated microglia/macrophages to drive immunosuppression.

Zirui Wang, Qifan Sun, Chunzhao Li, Tai Sun, Zhongning He, Yi Wang, Ruijie Li, Xiukun Lin, Miriam Galvonas Jasiulionis, Nan Ji and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zirui Wang *Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, PR China.
Qifan Sun *Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, PR China.
Chunzhao LiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
Tai SunDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
Zhongning HeDepartment of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, PR China.
Yi WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
Ruijie LiDepartment of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, PR China.
Xiukun LinLab of Food and Drug Safety, Shandong University of Political Science and Law, Jinan, PR China.
Miriam Galvonas JasiulionisDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
Nan JiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.ORCID http://orcid.org/0000-0002-9001-8858
Yang ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China. zhangyang@bjtth.org.ORCID http://orcid.org/0000-0001-8044-9040
Huanli XuDepartment of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, PR China. xuhuanli@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-4599-9271

Funding

Capital Health Research and Development of Special 2022-2-2047
6 · The paper itself

Abstract

backgroundGlioma immunotherapy faces major challenges due to the pervasive presence of glioma-associated microglia/macrophages (GAMs) and inadequate T-cell responses. LAIR1 is highly expressed in GAMs and correlates with poor glioma prognosis. This study investigated its role in GAMs and immunosuppression in glioma.

methodsLAIR1 expression was analysed via bioinformatics, flow cytometry, and multiplex immunohistochemical staining. Its function was studied using Lair1

resultsLAIR1 was predominantly expressed on GAMs, and high infiltration of LAIR1

conclusionLAIR1 is a critical phagocytosis suppressor in GAMs, driving glioma immunosuppression. Targeting LAIR1 represents a promising strategy to restore anti-tumour immunity.

Identifiers

PMID42850382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.